96 related articles for article (PubMed ID: 24937555)
1. Partial compliance with antipsychotics and its impact on patient outcomes.
Narasimhan M; Un Pae C; Masand N; Masand P
Int J Psychiatry Clin Pract; 2007; 11(2):102-11. PubMed ID: 24937555
[TBL] [Abstract][Full Text] [Related]
2. Partial compliance in schizophrenia and the impact on patient outcomes.
Llorca PM
Psychiatry Res; 2008 Nov; 161(2):235-47. PubMed ID: 18849080
[TBL] [Abstract][Full Text] [Related]
3. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
Kane JM; Leucht S; Carpenter D; Docherty JP;
J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
[TBL] [Abstract][Full Text] [Related]
4. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
5. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].
Misdrahi D; Llorca PM; Lançon C; Bayle FJ
Encephale; 2002; 28(3 Pt 1):266-72. PubMed ID: 12091789
[TBL] [Abstract][Full Text] [Related]
6. [Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based].
Schanda H; Stompe T
Neuropsychiatr; 2010; 24(1):14-26. PubMed ID: 20146916
[TBL] [Abstract][Full Text] [Related]
7. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
Bhanji NH; Chouinard G; Margolese HC
Eur Neuropsychopharmacol; 2004 Mar; 14(2):87-92. PubMed ID: 15013023
[TBL] [Abstract][Full Text] [Related]
8. The case for long-acting antipsychotic agents in the post-CATIE era.
Nasrallah HA
Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
[TBL] [Abstract][Full Text] [Related]
9. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
Turner MS; Stewart DW
J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
[TBL] [Abstract][Full Text] [Related]
10. Medication adherence and the use of long-acting antipsychotics in bipolar disorder.
El-Mallakh RS
J Psychiatr Pract; 2007 Mar; 13(2):79-85. PubMed ID: 17414683
[TBL] [Abstract][Full Text] [Related]
11. Partial compliance with antipsychotic medication is common in patients with schizophrenia.
Rummel-Kluge C; Schuster T; Peters S; Kissling W
Aust N Z J Psychiatry; 2008 May; 42(5):382-8. PubMed ID: 18473256
[TBL] [Abstract][Full Text] [Related]
12. Influences on therapist's decisions for neuroleptic treatment in schizophrenia: the role of characteristics of the patient and the physician.
Franz M; Ranger J; Hanewald B; Gallhofer B; Lay B
Pharmacopsychiatry; 2012 Nov; 45(7):261-8. PubMed ID: 22648306
[TBL] [Abstract][Full Text] [Related]
13. A review of second-generation antipsychotic discontinuation in first-episode psychosis.
Miller BJ
J Psychiatr Pract; 2008 Sep; 14(5):289-300. PubMed ID: 18832960
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological prevention of relapse.
Lader M
Kaohsiung J Med Sci; 1998 Jul; 14(7):448-57. PubMed ID: 9739577
[TBL] [Abstract][Full Text] [Related]
15. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
16. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 16():34-40. PubMed ID: 14680417
[TBL] [Abstract][Full Text] [Related]
17. Improving treatment adherence in patients with schizophrenia.
Kane JM
J Clin Psychiatry; 2011 Sep; 72(9):e28. PubMed ID: 21951990
[TBL] [Abstract][Full Text] [Related]
18. Facilitating compliance with antipsychotic medication.
Marder SR
J Clin Psychiatry; 1998; 59 Suppl 3():21-5. PubMed ID: 9541334
[TBL] [Abstract][Full Text] [Related]
19. The impact of antipsychotic side effects on attitudes towards medication in people with schizophrenia and related disorders.
Chiang YL; Klainin-Yobas P; Ignacio J; Chng CM
J Clin Nurs; 2011 Aug; 20(15-16):2172-82. PubMed ID: 21539628
[TBL] [Abstract][Full Text] [Related]
20. Improving patient outcomes in schizophrenia: achieving remission.
Nasrallah HA; Lasser R
J Psychopharmacol; 2006 Nov; 20(6 Suppl):57-61. PubMed ID: 17046987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
